CRC Research Update — October 14, 2026
Today's colorectal cancer research highlights
stage-iv
A collection of 27 issues
Recurrence drives long-term prognosis after liver metastasis resection
Skip to content
The CRC Digest
◆ TRIAL DATA
Recurrence drives long-term prognosis after liver metastasis resection
An international study of 3,002 patients who underwent hepatectomy for colorectal liver metastases found that 54% developed recurrence; multistate modeling showed that the probability of recurrence decreased the longer patients remained recurrence-free, and
CRC Research Update — October 12, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 07, 2026
Today's colorectal cancer research highlights
Zanidatamab shows activity in HER2-amplified metastatic colorectal cancer after multiple prior lines
Skip to content
The CRC Digest
▸ TREATMENT
Zanidatamab shows activity in HER2-amplified metastatic colorectal cancer after multiple prior lines
A case report demonstrates zanidatamab-based therapy as a potential option for HER2-positive metastatic disease, particularly in patients with cetuximab resistance driven by ERBB2 amplification. (Frontiers in Pharmacology)
This content is informational
Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer
Skip to content
The CRC Digest
▸ TREATMENT
Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer
A case report describes a 26-year-old woman with microsatellite-stable, BRAF V600E-mutant stage IVC disease who achieved complete remission with first-line immunotherapy and targeted therapy combination, without cytotoxic chemotherapy.
CRC Research Update — October 03, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 02, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 22, 2026
Today's colorectal cancer research highlights
Nutritional and inflammatory markers may predict outcomes in metastatic CRC
Skip to content
The CRC Digest
Nutritional and inflammatory markers may predict outcomes in metastatic CRC
A supplementary analysis of the JCOG1007 trial examined whether pretreatment modified Glasgow Prognostic Score, albumin, and C-reactive protein were associated with differential outcomes after upfront primary tumor resection. (Ann Surg Oncol)
This content is